The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2
Martina Morokutti-Kurz, Nicole Unger-Manhart, Philipp Graf, Pia Rauch, Julia Kodnar, Maximilian Große, Christian Setz, Markus Savli, Friedrich Ehrenreich, Andreas Grassauer, Eva Prieschl-Grassauer, Ulrich Schubert
International Journal of General Medicine, doi:10.2147/ijgm.s325861
The aim of this study was to investigate whether sucking of an iota-carrageenan containing lozenge releases sufficient iota-carrageenan into the saliva of healthy subjects to neutralize representatives of the most common respiratory virus families causing common cold and SARS-CoV-2. Patients and Methods: In this monocentric, open label, prospective clinical trial, 31 healthy subjects were included to suck a commercially available iota-carrageenan containing lozenge. Saliva samples from 27 subjects were used for ex vivo efficacy analysis. The study's primary objective was to assess if the mean iota-carrageenan concentration of the saliva samples exceeded 5 µg/mL, which is the concentration known to reduce replication of human rhinovirus (hRV) 1a and 8 by 90%. The iota-carrageenan concentration of the saliva samples was analyzed by UV-Vis spectroscopy. The antiviral effectiveness of the individual saliva samples was determined in vitro against a panel of respiratory viruses including hRV1a, hRV8, human coronavirus OC43, influenza virus A H1N1pdm09, coxsackievirus A10, parainfluenza virus 3 and SARS-CoV-2 using standard virological assays.
Results: The mean iota-carrageenan concentration detected in the saliva exceeds the concentration needed to inhibit 90% of hRV1a and hRV8 replication by 134-fold (95% CI 116.3-160.8-fold; p < 0.001). Thus, the study met the primary endpoint. Furthermore, the iota-carrageenan saliva concentration was 60 to 30,351-fold higher than needed to reduce viral replication/binding of all tested viruses by at least 90% (p < 0.001). The effect was most pronounced in hCoV OC43; in case of SARS-CoV-2, the IC 90 was exceeded by 121-fold (p < 0.001). Conclusion: Sucking an iota-carrageenan containing lozenge releases sufficient iota-carrageenan to neutralize and inactivate the most abundant respiratory viruses as well as pandemic SARS-CoV-2. The lozenges are therefore an appropriate measure to reduce the viral load at the site of infection, hereby presumably limiting transmission within a population as well as translocation to the lower respiratory tract. Trial Registration: NCT04533906.
Disclosure Martina Morokutti-Kurz, Nicole Unger-Manhart, Philipp Graf, Julia Kodnar are employed by Marinomed Biotech AG. Eva Prieschl-Grassauer and Andreas Grassauer are co-founder of Marinomed Biotech AG and inventor on patent #WO2008067982 held by Marinomed Biotech AG that relates to the content of the manuscript. Markus Savli reports personal fees from Marinomed Biotech AG. Andreas Grassauer, Eva Prieschl-Grassauer and Martina Morokutti-Kurz are inventors of a patent submission related to the content of the manuscript; the number of this patent application is EP20186334. The authors report no other conflicts of interest in this work.
International Journal of General Medicine
Dovepress
References
Charlton, Babady, Ginocchio, Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections, Clin Microbiol Rev,
doi:10.1128/CMR.00042-18Collins, Dawes, The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa, J Dent Res,
doi:10.1177/00220345870660080201Eccles, Meier, Jawad, Weinmüllner, Grassauer et al., Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir Res,
doi:10.1186/1465-9921-11-108Eccles, Winther, Johnston, Robinson, Trampisch et al., Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial, Respir Res,
doi:10.1186/s12931-015-0281-8Fazekas, Eickhoff, Pruckner, Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold, BMC Complement Altern Med,
doi:10.1186/1472-6882-12-147Graf, Bernkop-Schnürch, Egyed, Koller, Prieschl-Grassauer et al., Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis, Int J Gen Med,
doi:10.2147/IJGM.S167123Grassauer, Weinmuellner, Meier, Pretsch, Prieschl-Grassauer et al., Iota-carrageenan is a potent inhibitor of rhinovirus infection, Virol J,
doi:10.1186/1743-422X-5-107Große, Ruetalo, Businger, Evidence that quinine exhibits antiviral activity against SARS-CoV-2 infection in vitro, Preprints,
doi:10.2147/IJGM.S325861Hemilä, Chalker, Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: re-analysis of randomized trial data, Pharmacol Res Perspect
Huijghebaert, Vanham, Van Winckel, Allegaert, Does trypsin oral spray (Viruprotect ® / ColdZyme ® ) protect against COVID-19 and common colds or induce mutation? Caveats in medical device regulations in the European union, Int J Environ Res Public Health,
doi:10.3390/ijerph18105066Jang, Shin, Lee, Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2, Sci Rep,
doi:10.1038/s41598-020-80896-9Koenighofer, Lion, Bodenteich, Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med,
doi:10.1186/2049-6958-9-57Ludwig, Enzenhofer, Schneider, Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial, Respir Res,
doi:10.1186/1465-9921-14-124Morokutti-Kurz, Dovepress Powered by TCPDF
Morokutti-Kurz, Graf, Prieschl-Grassauer, Amylmetacresol/ 2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat, Int J Gen Med,
doi:10.2147/IJGM.S120665Schütz, Conzelmann, Fois, Carrageenan containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures, Am J Physiol Lung Cell Mol Physiol,
doi:10.1152/ajplung.00552.2020Snell, New treatments for viral respiratory tract infectionsopportunities and problems, J Antimicrob Chemother,
doi:10.1093/jac/47.3.251Yasir, Goyal, Bansal, Sonthalia, StatPearls [Internet
